Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.

Arthritis research & therapy - 12 Jul 2012

Wiese Michael D, Schnabl Matthew, O'Doherty Catherine, Spargo Llewellyn D, Sorich Michael J, Cleland Leslie G, Proudman Susanna M

Abstract excerpt

INTRODUCTION: Rational selection of disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis (RA) has many potential advantages, including rapid disease control, reduced long-term disability and reduced overall cost to the healthcare system. Inter-individual genetic differences are particularly attractive as markers to predict efficacy and toxicity, as they can be determined rapidly prior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arthritis, Rheumatoid

Share to Cohort Studies

Share to Cytochrome P-450 CYP2C19

Share to Diarrhea

Share to Follow-Up Studies

Share to Isoxazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 22784880
DOI: 10.1186/ar3911
PMCID: PMC3580556

Genes

ABCG2
DHODH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.PMID 22784880Read ↗

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.Semantic proximity Read ↗

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.Semantic proximity Read ↗

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.Semantic proximity Read ↗

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.Semantic proximity Read ↗

Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis.Semantic proximity Read ↗

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsSemantic proximity Read ↗

Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.Semantic proximity Read ↗

The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity.Semantic proximity Read ↗

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisSemantic proximity Read ↗

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.Semantic proximity Read ↗

Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.